Phase 2 N=8 FMT in Ulcerative Colitis-Associated Pouchitis
Ulcerative Colitis Associated Pouchitis
Primary: Number of Patients Who Experienced Improvement of Pouchitis Symptoms — 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=102 A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
Pouchitis
Primary: Percentage of Participants With Chronic or Recurrent Pouchitis Achieving Clinically Relevant Remission at Week 14 — 9.8; 31.4 percentage of participants — p=0.013
Phase 3 N=138 Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics
Pouchitis
Primary: Proportion of Patients With Endoscopic Remission — 3; 3 Participants
Phase 2 N=26 Fecal Microbiota Transplantation (FMT) in the Treatment of Pouchitis
Pouchitis · Ulcerative Colitis
Primary: Clinical Remission — 4; 5 Participants — p=0.183
N/A N=2,239 European Safety Registry in Ulcerative Colitis (P04808)
Ulcerative Colitis
Primary: Percentage of Participants Within Each of Nine Pre-specified Adverse Event (AE) Categories — 9.1; 3.4; 10.5; 13.0 Percentage of participants
Phase 2 N=33 Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease
Crohn's Disease
Primary: Safety and Tolerability of Ciprofloxacin — 25; 11; 9; 1 Adverse events
N/A N=26 Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
Phase 2 N=330 Long-Term Safety Of PF-00547659 In Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Who Withdrew From Treatment Due to…
Phase 3 N=32 Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Patients Who Achieved Clinical Response — 57; 35 percentage of patients — p=0.05
Phase 2 N=30 Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants Achieving Endoscopic Improvement — 16.7 percentage of participants
Phase 3 N=829 Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis
Ulcerative Colitis
Primary: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months — 83.7; 81.5 percent of participants
N/A N=13 Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis
Colitis, Ulcerative · Inflammatory Bowel Disease · IBD
Primary: Number of Participants to be Colectomy Free at 3 Months — 6 Participants
Phase 3 N=228 Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)
Ulcerative Colitis
Primary: Proportion of Subjects With Remission — 19; 13 Participants — p=>0.05
Phase 3 N=265 Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
Proctitis · Proctosigmoiditis
Primary: Percentage of Participants Who Achieved Remission — 38.3; 25.8 percentage of participants — p=0.0324
Phase 3 N=548 CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)
Ulcerative Colitis
Primary: Percentage of Patients Achieving Clinical Remission at Week 54 — 127; 30 Participants — p=<0.0001
Phase 3 N=281 Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
Proctitis · Proctosigmoiditis
Primary: Percentage of Participants Who Achieved Remission — 44.0; 22.4 percentage of participants — p=<0.0001
Phase 2 N=357 A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants in Clinical Remission at Week 12 — 2.7; 11.3; 16.7; 15.5 percentage of participants — p=0.0213
Phase 3 N=123 (CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.
Ulcerative Colitis
Primary: Percentage of Participants Achieving Clinical Remission — 76.7; 88.2; 92.0; 96.8 percentage of participants
N/A N=15 Autoimmune Protocol Diet and Inflammatory Bowel Disease
Crohn Disease · Ulcerative Colitis · Inflammatory Bowel Diseases
Primary: Number of Participants With Clinical Remission for Crohn's Disease — 6 Participants
Phase 2 N=15 Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis
Inflammatory Bowel Diseases · Ulcerative Colitis · Crohn Disease
Primary: 1. Safety and Tolerability of Universal Donor FMT Compared to Placebo: FMT-related Adverse Events Grade 2 or Above — 4; 0 Participants
Phase 4 N=52 Dose Escalation and Remission (DEAR)
Ulcerative Colitis
Primary: Fecal Calprotectin Level <50µg/g — 7; 1 participants
Phase 2 N=27 Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis
Ulcerative Colitis · Inflammatory Bowel Diseases
Primary: Clinical Response — 5; 2; 1 Participants
Phase 4 N=428 Predicting Response to Standardized Pediatric Colitis Therapy
Ulcerative Colitis
Primary: Number of Participants With Corticosteroid Free Remission (SFR) — 80; 70 Participants
Phase 3 N=276 Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)
Ulcerative Colitis
Primary: Proportion of Subjects With Remission at Month 6 — 82; 67 Participants — p=>0.05
Phase 4 N=30 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
Spondyloarthritis · Enterocolitis
Primary: Change Lewis Score Index — -225 units on a scale
Phase 3 N=30 Effect of Probiotic Supplementation on the Immune System in Patients With Ulcerative Colitis in Amman, Jordan
Ulcerative Colitis
Primary: The Level of Immunoglobulin (Ig) A — 270.42; 208.63 mg/dL
N/A N=46 Anal Human Papillomavirus in Inflammatory Bowel Disease Study
Inflammatory Bowel Disease (IBD) · Ulcerative Colitis (UC) · Crohn's Disease (CD)
Primary: Number of Participants With Anal HPV of Any Type, Single Type, and Multiple Types — 41; 16; 25 participants
Phase 3 N=817 TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)
Acute Ulcerative Colitis
Primary: Period 1: Clinical and Endoscopic Remission — 87; 95 Participants — p=0.005
Phase 2 N=50 Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.
Colitis, Ulcerative
Primary: Number of Participants With Treatment-Emergent Adverse Events, Serious Adverse Events, and Who Withdrew Due to Adverse Events — 33; 3; 8; 1 Participants
N/A N=4 Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova
Ulcerative Colitis
Primary: Change From Baseline of Mucus Production at 12 Weeks and 24 Weeks as Assessed by Histopathology